Publication: Prognostic effect of mean platelet volume in patients with coronary artery disease: A systematic review and meta-analysis
1
Issued Date
2015-01-01
Resource Type
ISSN
03406245
Other identifier(s)
2-s2.0-84983184245
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Thrombosis and Haemostasis. Vol.114, No.6 (2015), 1299-1309
Suggested Citation
Nakarin Sansanayudh, Pawin Numthavaj, Dittapol Muntham, Sukit Yamwong, Mark McEvoy, John Attia, Piyamitr Sritara, Ammarin Thakkinstian Prognostic effect of mean platelet volume in patients with coronary artery disease: A systematic review and meta-analysis. Thrombosis and Haemostasis. Vol.114, No.6 (2015), 1299-1309. doi:10.1160/TH15-04-0280 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/36799
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prognostic effect of mean platelet volume in patients with coronary artery disease: A systematic review and meta-analysis
Other Contributor(s)
Abstract
© Schattauer 2015. Large platelets with high haemostatic activity may lead to increased platelet aggregation.. Mean platelet volume (MPV), an indicator of platelet reactivity, may emerge as a prognostic marker in patients with coronary artery disease (CAD). It was the objective of this study to conduct a systematic review and meta-analysis to assess prognostic effects of MPV on cardiovascular events (CVE) in CAD patients. We searched MEDLINE and SCOPUS from inception to January 2, 2014. All studies that reported MPV and the incidence of cardiovascular events in CAD patients were included. Two reviewers independently extracted the data. A random-effects model was applied for pooling the mean difference of MPV between patients with vs without CVE. Among 30 eligible studies, eight studies reported mean difference of MPV between CVE groups, 11 studies reported MPV dichotomous into high vs low MPV groups, and 11 studies reported both. The pooled mean difference was 0.69 fL (95 %CI = 0.36, 1.01), i. e. patients with CVE had a MPV about 0.69 fL higher than non-CVE. Patients with higher MPV were about 12 % more likely to die than patients with lower MPV (RR 1.12; 95 %CI = 1.02-1.24). However, pooling these effects was based on high heterogeneity and the source of heterogeneity could not be identified. This might be explained by many differences among included studies (e. g. study population, outcomes of interest, analysate, time between blood collection and MPV analysis, etc). These findings suggest that MPV may be a useful prognostic marker in patients with CAD.